Octapharma has read with great interest the report prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH) on the cost-effectiveness of Octaplas® compared to FFP. This is the second version of this costeffectiveness report, which is entitled “Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budge...
